基因修饰内皮祖细胞在冠心病治疗中的研究进展

摘要

The pathogenesis of coronary heart disease is complex,one of the important pathogenesis is the imbalance in the coronary endothelial injury and repair.Currently,treatment of coronary heart disease mainly includes drug therapy,coronary artery bypass graft,bracket intervention and so on.Endothelial progenitor cells can differentiate into endothelial cells under certain conditions,to participate in angiogenesis.But the content of endothelial progenitor cells is very low in human tissues,it is far from enough for transplantation.In addition,several studies have shown that,compared with normal person,endothelial progenitor cells in patients with old age,diabetes,hypertension,coronary heart disease is less,and its function is significantly decreased.In recent years,many scholars put forward that gene modified endothelial progenitor cells can solve the above problems.The author reviews the research of genes modified endothelial progenitor cells transplantation treatment,to provide new ideas for clinical treatment of coronary heart disease.%冠心病的发病机制复杂，其中一个重要的发病机制是冠状动脉内皮损伤和修复两者间的平衡受到破坏。目前关于冠心病治疗方法主要包括药物治疗、冠脉搭桥、支架介入等。内皮祖细胞在一定条件下能分化为内皮细胞，参与血管新生。但是内皮祖细胞在人体组织中含量极低，远不够为移植治疗所用。另外，有多项研究显示，年龄大、冠心病、糖尿病、高血压患者的内皮祖细胞相比正常者量更少，且其功能显著下降。近年有许多学者提出通过基因修饰的内皮祖细胞能解决上述问题。下面笔者为基因修饰内皮祖细胞移植治疗的研究予以综述，为临床治疗冠心病提供新思路。